Mounjaro and Zepbound Sales Soar, Pushing Eli Lilly's (LLY) Q4 Revenue to New Highs
Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...
Eli Lilly records over twofold rise in diabetes/ obesity drugs in Q4
EST: Adds comments from Seeking Alpha analyst BioCGT Investor Eli Lilly (NYSE:LLY) on Thursday reported its Q4 2024 results, exceeding Wall Street forecasts and indicating a more than twofold rise in ...
Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines
Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...